17-DMAG
Water-soluble geldanamycin analogue
Catalog # ant-dgl-5, ant-dgl-25
For research use only
Version # 16G04-MM

PRODUCT INFORMATION

Contents:
17-DMAG is supplied as a lyophilized purple powder. It is available in two pack sizes:
- ant-dgl-5: 5 mg
- ant-dgl-25: 25 mg

Storage and stability:
- 17-DMAG is shipped at room temperature. Store lyophilized product at -20 °C. Protect from light. Lyophilized 17-DMAG is stable for 6 months when stored properly.
- Once solubilized 17-DMAG should be aliquoted and stored at -20 °C. Avoid repeated freeze-thaw cycles. Protect from light. Resuspended product is stable for 3 months when properly stored.

QUALITY CONTROL

• Purity: ≥92% (UHPLC)
• The absence of bacterial contamination (e.g. lipoproteins and endotoxins) is confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.

DESCRIPTION

17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG, also known as alvespimycin) is the first water-soluble analog of 17-AAG. This Hsp90 inhibitor shows promise in preclinical models. 17-DMAG has excellent bioavailability, is widely distributed to tissues, and is quantitatively metabolized much less than is 17-AAG. Clinical studies have shown that alvespimycin (KOS-1022) has therapeutic effects and is well tolerated in patients with solid tumours, advanced solid tumours or acute myeloid leukaemia, indicating that it has potential to be a new drug of choice for cancer therapy.


CHEMICAL PROPERTIES

CAS number: 467214-21-7
Synonyms: NSC 707545, Alvespimycin HCl
Formula: C_{32}H_{48}N_{4}O_{8} • HCl
Molecular weight: 653.2
Solubility: H_2O (10 mg/ml)
Structure:

The use of 17-DMAG is covered under US Patent 6,890,917 owned and licensed by the NIH to InvivoGen.

RELATED PRODUCTS

<table>
<thead>
<tr>
<th>Product</th>
<th>Catalog Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>17-AAG (GA analogue)</td>
<td>ant-agl-5</td>
</tr>
<tr>
<td>FITC-Geldanamycin</td>
<td>ant-fgl-1</td>
</tr>
<tr>
<td>Geldanamycin</td>
<td>ant-gl-5</td>
</tr>
</tbody>
</table>